KALA BIO completed a registered direct offering of 10 million shares at $1.00 per share, raising approximately $10 million. The company plans to use the proceeds to repay debt and for general corporate purposes.
KALA BIO, Inc. Common Stock (KALA)
Common Stock · Currency in USD · XNAS
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Company Info
SIC2834
Composite FIGIBBG001J2MVT8
CIK0001479419
IPOJul 20, 2017
Sectorpharmaceutical preparations
Highlights
Market Cap$155.11M
EPS-$4.28
P/E Ratio-5.13
Revenue$NaN
Gross Profit$0.00
Net Income-$30.26M
Employees38
WSO911,330,225
Phone781-996-5252
Websitehttps://www.kalarx.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in KALA BIO, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
KALA BIO, Inc. Common Stock (KALA) has returned -69.68% so far this year and -95.75% over the past 12 months. Looking at the last ten years, KALA has achieved an annualized return of -57.25%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
KALA
1M-38.78%
6M-88.65%
YTD-69.68%
1Y-95.75%
5Y-78.55%
10Y-57.25%
Benchmark (SPY)
1M-1.58%
6M-2.48%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of KALA BIO, Inc. Common Stock (KALA) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.59% | -24.71% | -54.45% | -5.44% | ||||||||
| 2025 | 24.49% | -23.59% | -20.31% | -31.96% | -3.12% | 28.65% | 44.04% | 70.52% | -87.28% | -46.58% | 20.76% | -57.24% |
| 2024 | -0.86% | 3.31% | 6.27% | -14.75% | 1.51% | 1.36% | -7.80% | -8.73% | -2.56% | 23.51% | -2.31% | 2.06% |
| 2023 | -46.45% | -41.04% | 49.75% | 6.92% | -6.96% | 2.03% | 2.24% | -10.17% | -33.33% | -22.65% | -13.45% | 20.48% |
| 2022 | -28.07% | -24.76% | 98.53% | -51.17% | -50.33% | -21.01% | 10.00% | -7.79% | -21.85% | -43.40% | -16.95% | 618.46% |
| 2021 | 7.99% | -1.85% | -11.32% | 12.52% | -27.75% | -7.02% | -34.66% | -2.31% | -22.02% | -33.33% | 7.95% | -37.63% |
| 2020 | 58.09% | -9.93% | 63.69% | 14.61% | 24.47% | -14.76% | -17.06% | 0.68% | -15.92% | -14.78% | 11.18% | -10.20% |
| 2019 | 14.97% | 51.17% | -2.36% | -7.62% | -28.83% | 16.21% | -9.26% | -31.27% | -6.28% | -4.47% | 13.62% | -13.18% |
| 2018 | -17.55% | -7.38% | 12.75% | -4.76% | 1.40% | -9.97% | -6.00% | 6.38% | -26.94% | -26.62% | -13.70% | -23.35% |
| 2017 | 20.24% | 27.39% | -10.43% | -30.39% | 19.39% | -2.99% |
Performance Indicators
The charts below present risk-adjusted performance metrics for KALA BIO, Inc. Common Stock (KALA) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of KALA compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current KALA BIO, Inc. Common Stock volatility is 9.30%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 55.48M | 55.95M | 86.82M | 139.43M | 221.61M | 154.32M | 220.97M | 116.13M |
| Equity Attributable To Parent (USD) | 12.33M | 7.50M | 18.97M | 16.80M | 100.00M | 29.69M | 104.98M | 89.68M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - |
| Equity (USD) | 12.33M | 7.50M | 18.97M | 16.80M | 100.00M | 29.69M | 104.98M | 89.68M |
| Commitments and Contingencies (USD) | - | - | - | - | - | - | - | - |
| Other Non-current Liabilities (USD) | - | - | - | 5.20M | 24.39M | 24.86M | 23.98M | - |
| Long-term Debt (USD) | - | - | 43.30M | 80.00M | 75.00M | 75.00M | 75.00M | 18.89M |
| Noncurrent Liabilities (USD) | 26.20M | 40.10M | 42.16M | 85.20M | 99.39M | 99.86M | 98.98M | 12.00M |
| Other Current Liabilities (USD) | 13.94M | 4.81M | 19.52M | 26.20M | 10.83M | 15.75M | 6.21M | 10.85M |
| Wages (USD) | 2.39M | 2.62M | 3.33M | 6.32M | 9.68M | 6.50M | 5.35M | 2.40M |
| Accounts Payable (USD) | 628.00K | 919.00K | 2.83M | 4.90M | 1.72M | 2.52M | 5.45M | 1.20M |
| Current Liabilities (USD) | 16.96M | 8.35M | 25.69M | 37.42M | 22.23M | 24.77M | 17.01M | 14.46M |
| Liabilities (USD) | 43.15M | 48.45M | 67.85M | 122.62M | 121.61M | 124.63M | 115.99M | 26.45M |
| Other Non-current Assets (USD) | 1.94M | 2.33M | 478.00K | 12.34M | 47.06M | 46.14M | 41.77M | 134.00K |
| Fixed Assets (USD) | 749.00K | 753.00K | 400.00K | 2.72M | 3.17M | 2.70M | 2.17M | 786.00K |
| Noncurrent Assets (USD) | 2.69M | 3.08M | 878.00K | 15.06M | 50.23M | 48.84M | 43.94M | 920.00K |
| Other Current Assets (USD) | - | - | - | 115.73M | 166.15M | 100.84M | 172.93M | - |
| Inventory (USD) | - | - | - | 8.64M | 5.23M | 4.65M | 4.10M | - |
| Current Assets (USD) | 52.80M | 52.87M | 85.94M | 124.37M | 171.38M | 105.48M | 177.03M | 115.21M |
| Assets (USD) | 55.48M | 55.95M | 86.82M | 139.43M | 221.61M | 154.32M | 220.97M | 116.13M |
News and Insights
U.S. stocks traded mixed on Monday, with the Dow Jones falling slightly while NASDAQ rose. Carnival reported strong Q3 earnings, while several biotech stocks experienced significant price drops. Oil prices declined, and U.S. pending home sales surged in August.
Multiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.
U.S. stocks traded higher with Nasdaq gaining 150 points. Pending home sales surged 4% in August, marking the sharpest gain in five months. Several biotech companies experienced significant stock price movements.
Clinical-stage biotech Kala Bio reported a Q2 2025 net loss of $1.71 per share, with continued focus on developing KPI-012 for persistent corneal epithelial defects. The company completed patient enrollment in its Phase 2b CHASE trial and expects topline results by September 2025.
KALA BIO, Inc. announced the resignation of its CEO Mark Iwicki and the appointment of Todd Bazemore as interim CEO. Iwicki will continue to serve as Chair of the Board. Bazemore has over 30 years of experience in the pharmaceutical industry and will lead the company as it approaches topline data from the ongoing Phase 2b clinical trial of its lead product candidate KPI-012 for the treatment of persistent corneal epithelial defect (PCED).
KALA BIO, a clinical-stage biopharmaceutical company, announced that its Head of R&D and Chief Medical Officer will present at the Piper Sandler 36th Annual Healthcare Conference. The company is focused on developing innovative therapies for rare and severe eye diseases.
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 5, 2024.
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.